King Luther Capital Management Corp Acquires 8,263 Shares of Thermo Fisher Scientific Inc. $TMO

King Luther Capital Management Corp grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 688,382 shares of the medical research company’s stock after buying an additional 8,263 shares during the quarter. Thermo Fisher Scientific makes up approximately 1.6% of King Luther Capital Management Corp’s portfolio, making the stock its 14th largest holding. King Luther Capital Management Corp’s holdings in Thermo Fisher Scientific were worth $398,883,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also modified their holdings of the company. Brighton Jones LLC raised its holdings in Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after acquiring an additional 988 shares during the period. Revolve Wealth Partners LLC raised its holdings in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares in the last quarter. Darwin Wealth Management LLC bought a new position in Thermo Fisher Scientific in the second quarter worth $170,000. Raymond James Financial Inc. lifted its holdings in shares of Thermo Fisher Scientific by 7.4% during the 2nd quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock worth $315,781,000 after acquiring an additional 53,542 shares during the period. Finally, California State Teachers Retirement System lifted its stake in Thermo Fisher Scientific by 0.4% during the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock worth $244,099,000 after purchasing an additional 2,262 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $448.88 on Wednesday. The stock has a market capitalization of $166.81 billion, a price-to-earnings ratio of 24.68, a PEG ratio of 1.98 and a beta of 0.88. The firm has a fifty day simple moving average of $479.41 and a 200 day simple moving average of $536.31. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The business had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.Thermo Fisher Scientific’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares in the company, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Citigroup lifted their price objective on Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a “buy” rating in a report on Friday, January 30th. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday. Jefferies Financial Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Barclays reduced their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. Finally, UBS Group reissued a “neutral” rating and issued a $615.00 price target on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $616.10.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.